NYSEAMERICAN:CYBN Cybin (CYBN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CYBN Stock Alerts $0.35 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.3550-Day Range N/A52-Week Range$0.21▼$0.74Volume2.16 million shsAverage Volume5.05 million shsMarket Capitalization$143.80 millionP/E RatioN/ADividend YieldN/APrice Target$4.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Cybin alerts: Email Address Cybin MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,114.3% Upside$4.25 Price TargetShort InterestBearish3.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCybin has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.64% of the float of Cybin has been sold short.Short Interest Ratio / Days to CoverCybin has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Cybin has recently increased by 1.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYBN. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 19 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.94% of the stock of Cybin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($0.22) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Cybin Stock (NYSEAMERICAN:CYBN)Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.Read More CYBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYBN Stock News HeadlinesApril 5, 2024 | theglobeandmail.comLSD, Ecstasy, magic mushrooms coming to a clinic near you? Legalization nears for psychedelicsApril 1, 2024 | msn.comInside George Soros’ Portfolio: His Top 8 Stock PicksApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 1, 2024 | msn.com10 Best Stocks To Buy Under $1March 31, 2024 | msn.comFan invades the pitch smoking marijuana and sniffing glue in BrazilMarch 30, 2024 | msn.comPsychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And MoreMarch 20, 2024 | msn.comPsyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And MoreMarch 15, 2024 | msn.comCybin initiates Phase 2 study for psychedelic drug DMTApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 13, 2024 | msn.comFDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementMarch 13, 2024 | msn.comCybin spikes after FDA breakthrough tag for psychedelic therapyMarch 13, 2024 | finance.yahoo.comAnnounces Oversubscribed Private Placement of U.S. $150 MillionFebruary 27, 2024 | finance.yahoo.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comCybin Stock (AMEX:CYBN) Earnings Dates and Earning CallsFebruary 17, 2024 | finance.yahoo.comALPN Mar 2024 25.000 callFebruary 16, 2024 | benzinga.comCybin Inc. Q3 Earnings: Clinical Advances Amid Financial LossJanuary 9, 2024 | msn.comCybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical ResultsJanuary 4, 2024 | finance.yahoo.comCybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development ProgramsDecember 5, 2023 | finance.yahoo.comCybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline ResultsNovember 16, 2023 | finance.yahoo.comCybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023November 15, 2023 | finance.yahoo.comCybin Announces Poster Presentation at Neuroscience 2023 Annual MeetingNovember 14, 2023 | benzinga.comThinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin?October 31, 2023 | finance.yahoo.comCybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single DoseOctober 31, 2023 | finance.yahoo.comCybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023October 25, 2023 | finance.yahoo.comCybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT ProgramOctober 23, 2023 | msn.comPsychedelic drug developer Cybin completes acquisition of Small PharmaOctober 23, 2023 | finance.yahoo.comCybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic TherapeuticsSee More Headlines Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/27/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:CYBN CUSIPN/A CIKN/A Webwww.cybin.com Phone908-764-8385FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.25 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,114.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.05% Return on Assets-97.85% Debt Debt-to-Equity RatioN/A Current Ratio5.76 Quick Ratio5.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.84Miscellaneous Outstanding Shares410,860,000Free Float349,227,000Market Cap$143.80 million OptionableNot Optionable Beta0.43 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Eric So L.L.B. (Age 48)Co-Founder, President & Executive Chairman Comp: $452.11kMr. Douglas L. Drysdale (Age 54)Chief Executive Officer Comp: $604.39kMr. Paul Glavine (Age 35)Co-Founder, Chief Growth Officer & Director Comp: $452.11kMr. Greg Cavers (Age 53)Chief Financial Officer Comp: $238.52kMr. Aaron BartloneChief Operating OfficerMr. John Kanakis (Age 44)Co-Founder Comp: $693.64kDr. Alex L. Nivorozhkin Ph.D. (Age 64)Chief Scientific Officer Ms. Lori ChallengerChief Compliance, Ethics & Administrative OfficerMr. Gabriel Fahel (Age 48)Chief Legal Officer & Corporate Secretary Sara Brittany SomersetChief Communications OfficersMore ExecutivesKey CompetitorsINmune BioNASDAQ:INMBscPharmaceuticalsNASDAQ:SCPHGenfitNASDAQ:GNFTNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCSold 91,261 shares on 2/14/2024Ownership: 0.453%Rathbones Group PLCBought 65,381 shares on 2/13/2024Ownership: 0.016%PDS Planning IncBought 1,153,120 shares on 2/1/2024Ownership: 0.281%View All Institutional Transactions CYBN Stock Analysis - Frequently Asked Questions Should I buy or sell Cybin stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYBN shares. View CYBN analyst ratings or view top-rated stocks. What is Cybin's stock price target for 2024? 4 equities research analysts have issued 12-month target prices for Cybin's shares. Their CYBN share price targets range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.25 in the next twelve months. This suggests a possible upside of 1,114.3% from the stock's current price. View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts. How have CYBN shares performed in 2024? Cybin's stock was trading at $0.4135 at the beginning of 2024. Since then, CYBN stock has decreased by 15.4% and is now trading at $0.35. View the best growth stocks for 2024 here. Are investors shorting Cybin? Cybin saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 23,050,000 shares, an increase of 146.5% from the February 29th total of 9,350,000 shares. Based on an average daily volume of 5,100,000 shares, the short-interest ratio is currently 4.5 days. Approximately 6.6% of the company's shares are short sold. View Cybin's Short Interest. How were Cybin's earnings last quarter? Cybin Inc. (NYSEAMERICAN:CYBN) issued its earnings results on Wednesday, February, 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.04. What ETF holds Cybin's stock? Simplify Propel Opportunities ETF holds 500,000 shares of CYBN stock, representing 0.19% of its portfolio. How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:CYBN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
